


PHARMACEUTICAL 2019

Zyla Life Sciences Rank 309 of 371





PHARMACEUTICAL 2019

Zyla Life Sciences Rank 309 of 371

The relative strengths and weaknesses of Zyla Life Sciences are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zyla Life Sciences compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 339% points. The greatest weakness of Zyla Life Sciences is the variable Other Expenses, reducing the Economic Capital Ratio by 421% points.

The company's Economic Capital Ratio, given in the ranking table, is -588%, being 256% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	54,517
Cost of Goods Sold	0
Intangible Assets	4,281
Liabilities, Current	33,145
Liabilities, Non-Current	0
Other Assets	2,076
Other Compr. Net Income	-38,004
Other Expenses	60,327
Other Liabilities	0
Other Net Income	0
Property and Equipment	1,059
Research and Development	3,536
Revenues	30,353
Selling, General and Administrative Expense	24,079

Output Variable	Value in 1000 USD
Assets	61,933
Liabilities	33,145
Expenses	87,942
Stockholders Equity	28,788
Net Income	-57,589
Comprehensive Net Income	-76,591
Economic Capital Ratio	-588%